These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

167 related items for PubMed ID: 2519864

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Comparison of intestinal toxic effects of platinum complexes: cisplatin (CDDP), carboplatin (CBDCA), and iproplatin (CHIP).
    Kralovánszky J, Prajda N, Kerpel-Fronius S, Gál F, Kiss F.
    Cancer Chemother Pharmacol; 1988; 21(1):40-4. PubMed ID: 3277733
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Vestibular morphological analysis of the effects of cisplatin vs. platinum analogs, CBDCA (JM-8) and CHIP (JM-9).
    Schweitzer VG, Rarey KE, Dolan DF, Abrams GE, Sheridan C.
    Laryngoscope; 1986 Sep; 96(9 Pt 1):959-74. PubMed ID: 3528727
    [Abstract] [Full Text] [Related]

  • 8. Stable circadian mechanisms of toxicity of two platinum analogs (cisplatin and carboplatin) despite repeated dosages in mice.
    Boughattas NA, Lévi F, Fournier C, Hecquet B, Lemaigre G, Roulon A, Mathé G, Reinberg A.
    J Pharmacol Exp Ther; 1990 Nov; 255(2):672-9. PubMed ID: 2243347
    [Abstract] [Full Text] [Related]

  • 9. Increased therapeutic efficacy induced by tumor necrosis factor alpha combined with platinum complexes and whole-body hyperthermia in rats.
    Ohno S, Strebel FR, Stephens LC, Siddik ZH, Makino M, Klostergaard J, Tomasovic SP, Khokhar AR, Bull JM.
    Cancer Res; 1992 Aug 01; 52(15):4096-101. PubMed ID: 1638521
    [Abstract] [Full Text] [Related]

  • 10. Platinum agents in the treatment of osteosarcoma: efficacy of cisplatin vs. carboplatin in human osteosarcoma cell lines.
    Robson H, Meyer S, Shalet SM, Anderson E, Roberts S, Eden OB.
    Med Pediatr Oncol; 2002 Dec 01; 39(6):573-80. PubMed ID: 12376980
    [Abstract] [Full Text] [Related]

  • 11. Chromosomal aberrations, sister chromatid exchange (SCEs) and micronuclei induction with three platinum compounds (cis-DDP, CHIP, CBDCA) in V79 cells in vitro.
    Plesková I, Blasko M, Siracký J.
    Neoplasma; 1984 Dec 01; 31(6):655-9. PubMed ID: 6395027
    [Abstract] [Full Text] [Related]

  • 12. Immunocytochemical detection of interaction products of cis-diamminedichloroplatinum(II) and cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II) with DNA in rodent tissue sections.
    Terheggen PM, Floot BG, Scherer E, Begg AC, Fichtinger-Schepman AM, den Engelse L.
    Cancer Res; 1987 Dec 15; 47(24 Pt 1):6719-25. PubMed ID: 3315190
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA.
    Knox RJ, Friedlos F, Lydall DA, Roberts JJ.
    Cancer Res; 1986 Apr 15; 46(4 Pt 2):1972-9. PubMed ID: 3512077
    [Abstract] [Full Text] [Related]

  • 16. Selective protection against cis-diamminedichloroplatinum(II)-induced toxicity in kidney, gut, and bone marrow by diethyldithiocarbamate.
    Bodenner DL, Dedon PC, Keng PC, Katz JC, Borch RF.
    Cancer Res; 1986 Jun 15; 46(6):2751-5. PubMed ID: 3009000
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Lung tumour growth delay and normal tissue toxicity induced by three cytotoxic platinum drugs.
    van Rongen E, Kal HB, Kuijpers WC, van Berkel AH.
    Strahlenther Onkol; 1992 May 15; 168(5):300-7. PubMed ID: 1598667
    [Abstract] [Full Text] [Related]

  • 19. Ototoxicity of cisplatin vs. platinum analogs CBDCA (JM-8) and CHIP (JM-9).
    Schweitzer VG, Rarey KE, Dolan DF, Abrams G, Litterst CJ, Sheridan C.
    Otolaryngol Head Neck Surg; 1986 Apr 15; 94(4):458-70. PubMed ID: 3086808
    [Abstract] [Full Text] [Related]

  • 20. Use of a toxicity factor to explain differences in nephrotoxicity and myelosuppression among the platinum antitumour derivatives cisplatin, carboplatin and nedaplatin in rats.
    Hanada K, Asano K, Nishimura T, Chimata T, Matsuo Y, Tsuchiya M, Ogata H.
    J Pharm Pharmacol; 2008 Mar 15; 60(3):317-22. PubMed ID: 18284811
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.